uploads/2018/03/Chart-05-3-1.jpg

How Eli Lilly’s Endocrine Products Performed in 4Q17

By

Updated

Endocrine products

Eli Lilly and Company’s (LLY) Human Pharmaceuticals segment includes the endocrine products Humalog, Humulin, and Forteo. In 4Q17, Humalog and Forteo reported revenue rises, while Humulin’s revenue fell.

Chart 05

The chart above compares the revenues of LLY’s key endocrine products since 1Q16.

Article continues below advertisement

Forteo

Forteo, an osteoporosis drug, reported a 21% rise in revenue to ~$513.0 million in 4Q17 compared to ~$422 million in 4Q16. The growth in Forteo’s sales was driven by strong sales in both US and international markets. The drug’s US sales rose 32%, and its international sales rose 8% during the quarter.

Humalog

Humalog products are mealtime insulin products. Humalog reported a 5% fall in revenue to $782.0 million in 4Q17 compared to ~$820.0 million in 4Q16. The fall in Humalog’s revenue was driven by the lower sales in US markets and partially offset by strong sales in international markets. The drug’s US sales fell 12%, and its international sales rose 8% during the quarter.

Article continues below advertisement

Humulin

Humulin products are concentrated insulin products. Humulin reported a 2% rise in revenue to $363.0 million in 4Q17 compared to 4Q16. The rise in its revenue was driven by strong sales in US markets and partially offset by lower sales in international markets. The drug’s US sales rose 13%, and its international sales fell 15% during the quarter.

The SPDR S&P Pharmaceuticals ETF (XPH) holds 4.1% of its total investments in Eli Lilly, 4.2% in Merck & Co. (MRK), 4.4% in Allergan (AGN), and 4.1% in Johnson & Johnson (JNJ).

 

Advertisement

More From Market Realist